Company: CYTK
Filing Date: 2025-03-31
Form Type: PRE 14A
Source: 0001140361-25-011212
Chunk: 72

Company: CYTOKINETICS INC
Filing Date: 2025-03-31
Form: PRE 14A
Chunk 72
---
 Complete CY 9011 with data supportive of advancing CK-586 to Phase 2; and |

| • | Begin Phase 2 trial for CK-586. |

| • | Goals attributable to the continuing development of our early-stage drug candidates: |

| • | CK-136: Reach Go / No Go Decision; and |

| • | CK-089: Resolve partial hold and initiate Ph 1 trial. |

| • | G&A Objectives: |

| • | Partner with the CEO to achieve the following objectives: (i) Communicate Company progress against objectives to current investors, potential investors and analysts; and (ii) Achieve funding goal to generate at last $650M in committed capital via an equity raise, corporate partnership, and/or structured financing. |

| • | Goals attributable to the continuing development of Omecamtiv Mecarbil: |

| • | Prepare and participate in Oral Explanation hearing to reach final CHMP decision on MAA for omecamtiv mecarbil; |

| • | Finalize protocol for confirmatory trial (CY 1033) and present to Board for funding decision; and |

| • | If funded, initiate CY 1033. |

| • | Goals attributable to our scientific research: |

| • | Progress a specific research program to Development Candidate selection; and |

| • | Achieve measurable and specific objectives with respect to our ongoing research programs. |

| • | Personal development and leadership goals. |

| • | Mr. Lee's individual goals for 2024 included: |

| • | Goals attributable to capital structure and allocation: |

| • | Develop recommendation to de-risk 2027 convertible notes; |

| • | Evolve budget process to support complexity and growth of business, stress test and balance internal demands with external growth expectations; |

| • | Make recommendation and implement evolved financial guidance; and |

| Cytokinetics, Inc.|2025 Proxy Statement |     | 49 |

TABLE OF CONTENTS Executive Compensation

| • | Support IR efforts by developing process and deliverables to clearly communicate to investors about our financials. |

| • | Goals attributable to SEC Compliance. |

| • | Goals attributable to Facilities Management: |

| • | Execute agreement with our landlord to extend deadline to complete build-out of floor 6 and floor 7 of our headquarters; and |

| • | Finalize budget for floor 6 and 7 expansion. |

| • | Goals attributable to Information Technology Management: |

| • | Rationalize IT